Rate of progression of Alzheimer's disease is associated with genetic risk
L. A. Farrer, L. A. Cupples, C. M. van Duijn, L. Connor-Lacke, D. K. Kiely and J. H. Growdon
Department of Neurology, Boston (Mass) University School of Medicine, USA.
OBJECTIVE: To determine whether differences in genetic origin affect the
clinical course of Alzheimer's disease (AD). The limited number of cases of
AD linked to a known genetic abnormality is a major obstacle in determining
whether the disorder is expressed differently in patients with familial AD
and those with sporadic AD. DESIGN: Cross-sectional study. SETTING: Memory
Disorders Unit of the Alzheimer's Disease Research Center at Massachusetts
General Hospital, Boston. PARTICIPANTS: A total of 186 patients who had a
clinical diagnosis of probable AD, family history information available for
all first-degree relatives, and three or more outpatient visits were
identified from a consecutive case series. MAIN OUTCOME MEASURES: Rate of
decline on the Blessed Dementia Scale and the Activities of Daily Living
Scale. RESULTS: We calculated the probability that an individual patient
has a major genetic locus for AD (MGAD) using an algorithm that
incorporates information from a genetic model and the individual's family.
We measured cognitive and functional changes by the average annual rate of
increase (slope) in scores for the Blessed Dementia Scale and Activities of
Daily Living Scale, respectively. Multivariate analysis adjusted for age at
onset, duration of illness at entry into the study, and education level
indicated that scores on the Activities of Daily Living Scale worsened
significantly faster in men with MGAD than in men with non-MGAD. No
differences in Activities of Daily Living Scale slopes were observed among
women with MGAD and non-MGAD. The slopes for Blessed Dementia Scale scores
were similar in men and women regardless of the MGAD probability.
CONCLUSIONS: Genetic factors may account for heterogeneity in rates of
functional decline in AD. This study also illustrates the practical
application of a probabilistic method that characterizes the genetic status
of AD in an individual patient.